DNA methylation in bipolar disorder: mechanistic insights and translational challenges
Frontiers in Pharmacology · 24.07.2026 · 17
DOI: 10.3389/fphar.2026.1871913 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 24.07.2026. Verfasst von Lu Sun und 8 weiteren Autor:innen. Beteiligte Einrichtung: Encephalopathy Center, The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, China. Die Arbeit nennt 96 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Henan Provincial Science and Technology Research Project.
Abstract (Originalsprache)
Bipolar disorder (BD) is a severe and recurrent psychiatric disorder characterized by alternating manic, hypomanic, and depressive episodes, frequent comorbidity, high relapse rates, and an increased risk of suicide. Although the pathophysiology of BD remains incompletely understood, increasing evidence suggests that DNA methylation may represent an important epigenetic regulatory layer involved in BD-related biological heterogeneity. DNA methylation alterations have been reported in genes related to dopamine, serotonin, glutamate, and gamma-aminobutyric acid (GABA) systems, suggesting a potential role in neurotransmitter dysregulation. In addition, methylation changes in genes involved in neurotrophic signaling and ion-channel function may contribute to altered neuroplasticity and neuronal excitability. Clinically, candidate methylation signatures, including brain-derived neurotrophic factor (BDNF)-related methylation changes, specific GRIN2B CpG sites, and epigenetic age acceleration (EAA), have attracted attention for their potential relevance to diagnostic differentiation, disease progression, and treatment-response research. However, these signatures have not been clinically validated, and their reproducibility, tissue specificity, and longitudinal stability remain uncertain. Mood stabilizers, including lithium, valproate, and atypical antipsychotics, may partly influence methylation-related pathways, although their epigenetic effects and clinical significance remain incompletely defined. DNA methylation-targeted interventions remain experimental and require further validation regarding specificity, safety, blood–brain barrier delivery, and clinical applicability. This review summarizes current evidence on DNA methylation abnormalities in BD, focusing on neurotransmitter systems, neuroplasticity, ion-channel excitability, circadian rhythm, immune-inflammatory regulation, candidate methylation signatures and translational challenges. We emphasize that most available findings remain associative rather than causal, and future longitudinal, brain-region-specific, cell-type-resolved, and multi-omics studies are needed to clarify the mechanistic and translational relevance of DNA methylation in BD.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Encephalopathy Center, The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, China.
- The First Clinical Medical School, Henan University of Chinese Medicine, Zhengzhou, China.
- The Third Clinical Medical School (College of Acupuncture and Tuina), Henan University of Traditional Chinese Medicine, Zhengzhou, China.
- Joint Institute of Management and Science University at Henan University of Chinese Medicine, Zhengzhou, China.
- Henan Provincial Engineering Research Center for Intelligent Applications in Traditional Chinese Medicine Internet Hospitals, Zhengzhou, China.
- Henan University of Chinese Medicine Traditional Chinese Medicine (Zhongjing College), Zhengzhou, China.
Förderung
- Henan Provincial Science and Technology Research Project
Zitieren
APA
Sun, L., Yang, Y., Liu, T., Zhu, H. R., Wang, Y. G., Huang, Y. F., Lin, Z. X., Feng, Y. C., & Liu, F. X. (2026). DNA methylation in bipolar disorder: mechanistic insights and translational challenges. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1871913
Vancouver
Sun L, Yang Y, Liu T, Zhu HR, Wang YG, Huang YF, et al. DNA methylation in bipolar disorder: mechanistic insights and translational challenges. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1871913
BibTeX
@article{Sun2026,
author = {Sun, Lu and Yang, Ying and Liu, Tong and Zhu, Hang-Ran and Wang, Yi-Ge and Huang, Ya-Fei and Lin, Zi-Xuan and Feng, Yan-Chen and Liu, Fei-Xiang},
title = {DNA methylation in bipolar disorder: mechanistic insights and translational challenges},
journal = {Frontiers in Pharmacology},
year = {2026},
volume = {17},
doi = {10.3389/fphar.2026.1871913}
}
EUVIMED